Lung Cancer Therapeutics Market Trends and Forecast 2025-2029

The lung cancer therapeutics market size is projected to grow by USD 12.37 billion, at a CAGR of 8.3% between 2024 and 2029.The market is experiencing significant growth due to the increasing prevalence of lung cancer and advancements in precision medicine. Precision medicine, leveraging genetic information for targeted therapies, is transforming the treatment landscape. Immunotherapy is gaining traction for its ability to enhance the immune response against tumors. Additionally, regenerative therapies are emerging as new treatment avenues. While chemotherapy remains a key treatment option, its limitations are fostering demand for alternative therapies. The market is poised for steady growth, emphasizing the development of more effective and less toxic treatments.

For more details about the industry, get the PDF sample report for free

Market Segmentation

Therapy

• Targeted therapy

• Immunotherapy

• Chemotherapy

Type

• NSCLC

• SCLC

End-user

• Hospitals and specialist clinics

• Research institutions and academic centers

• Other

Geography

• North America

  • Canada

  • US

• Europe

  • Germany

  • UK

  • France

  • Spain

• Asia

  • China

  • India

  • Japan

  • South Korea

• Rest of World (ROW)

By Therapy Insights

The targeted therapy segment is expected to see notable growth, driven by the rising incidence of lung cancer and lifestyle factors such as tobacco use, pollution, and second-hand smoke exposure. Advances in precision medicine and nanomedicine are also contributing to market expansion. However, treatment side effects remain a concern.

Market Dynamics

Drivers

• High adoption of immunomodulators: PD-1 and PD-L1 inhibitors, including KEYTRUDA, IMFINZI, TECENTRIC, and OPDIVO, have shown superior clinical outcomes in NSCLC and SCLC treatment. The increasing approval of these therapies is driving market growth. Additionally, unhealthy lifestyles, pollution, and co-morbidities like heart disease, strokes, and diabetes contribute to the high prevalence of lung cancer.

Trends

• Emergence of regenerative therapies: Companies are investing in regenerative medicine, including gene therapies, to enhance lung cancer treatment outcomes. Targeted therapies focusing on genetic abnormalities linked to NSCLC are gaining prominence.

Challenges

• Preference for alternative treatment options: Surgery and radiation therapy remain preferred choices for early-stage lung cancer due to cost-effectiveness. However, chemotherapy, targeted therapy, and immunotherapy are crucial for managing advanced cases. Severe side effects from existing therapies necessitate the development of improved treatment modalities.

Get more details by ordering the complete report

Key Players

• AbbVie Inc.

• Amgen Inc.

• Astellas Pharma Inc.

• AstraZeneca Plc

• Boehringer Ingelheim International GmbH

• Bristol Myers Squibb Co.

• Daiichi Sankyo Co. Ltd.

• Eli Lilly and Co.

• F. Hoffmann La Roche Ltd.

• Galecto Inc.

• GlaxoSmithKline Plc

• IOVANCE Biotherapeutics Inc.

• Johnson and Johnson Services Inc.

• Merck and Co. Inc.

• Moderna Inc.

• Novartis AG

• Parexel International Corp.

• Pfizer Inc.

• Sanofi SA

• Takeda Pharmaceutical Co. Ltd.